IL263273B2 - Antibodies against GITR and their uses - Google Patents

Antibodies against GITR and their uses

Info

Publication number
IL263273B2
IL263273B2 IL263273A IL26327318A IL263273B2 IL 263273 B2 IL263273 B2 IL 263273B2 IL 263273 A IL263273 A IL 263273A IL 26327318 A IL26327318 A IL 26327318A IL 263273 B2 IL263273 B2 IL 263273B2
Authority
IL
Israel
Prior art keywords
seq
gitr
antibody
antibodies
antigen
Prior art date
Application number
IL263273A
Other languages
English (en)
Hebrew (he)
Other versions
IL263273B1 (en
IL263273A (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL263273A publication Critical patent/IL263273A/en
Publication of IL263273B1 publication Critical patent/IL263273B1/en
Publication of IL263273B2 publication Critical patent/IL263273B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL263273A 2016-06-10 2017-06-09 Antibodies against GITR and their uses IL263273B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662348353P 2016-06-10 2016-06-10
US201662432023P 2016-12-09 2016-12-09
US201762500312P 2017-05-02 2017-05-02
PCT/US2017/036818 WO2017214548A1 (en) 2016-06-10 2017-06-09 Anti-gitr antibodies and uses thereof

Publications (3)

Publication Number Publication Date
IL263273A IL263273A (en) 2018-12-31
IL263273B1 IL263273B1 (en) 2025-06-01
IL263273B2 true IL263273B2 (en) 2025-10-01

Family

ID=59078260

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263273A IL263273B2 (en) 2016-06-10 2017-06-09 Antibodies against GITR and their uses

Country Status (19)

Country Link
US (3) US10738126B2 (OSRAM)
EP (2) EP4344748A3 (OSRAM)
JP (2) JP7162535B2 (OSRAM)
KR (1) KR102495601B1 (OSRAM)
CN (1) CN109563170B (OSRAM)
AU (1) AU2017278193B9 (OSRAM)
BR (1) BR112018075434A2 (OSRAM)
CA (1) CA3027121A1 (OSRAM)
CL (1) CL2018003515A1 (OSRAM)
CO (1) CO2018013298A2 (OSRAM)
IL (1) IL263273B2 (OSRAM)
MA (1) MA45233A (OSRAM)
MX (2) MX2018015350A (OSRAM)
MY (1) MY200162A (OSRAM)
PH (1) PH12018502502A1 (OSRAM)
SG (1) SG11201810525XA (OSRAM)
UA (1) UA128687C2 (OSRAM)
WO (1) WO2017214548A1 (OSRAM)
ZA (1) ZA201807920B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
AU2017278193B9 (en) 2016-06-10 2024-02-01 Regeneron Pharmaceuticals, Inc. Anti-GITR antibodies and uses thereof
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
CN110168105B (zh) 2016-12-09 2024-05-24 瑞泽恩制药公司 用于对t细胞受体进行测序的系统和方法及其用途
WO2019175222A1 (en) * 2018-03-13 2019-09-19 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP2022519631A (ja) 2019-02-12 2022-03-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
CN114901695A (zh) * 2020-01-02 2022-08-12 南京金斯瑞生物科技有限公司 抗gitr抗体及其用途
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
IL296043A (en) 2020-03-06 2022-10-01 Regeneron Pharma Anti-gitro antibodies and their uses
TW202237642A (zh) * 2021-01-08 2022-10-01 美商１０Ｘ基因組學有限公司 對冠狀病毒具有特異性的抗原結合多肽及其用途
CN116761622A (zh) * 2021-01-08 2023-09-15 苏州丁孚靶点生物技术有限公司 药物产品及其用途
WO2022240161A1 (ko) * 2021-05-10 2022-11-17 메디맵바이오 주식회사 항-gitr 항체 및 이의 용도
CA3243774A1 (en) 2022-03-15 2023-09-21 Yeda Research And Development Co. Ltd. Anti-Glucocorticoid-Induced TNFR-Related Protein (GITR) Antibodies and Their Uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105021A2 (en) * 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
US8709424B2 (en) * 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
US20150064204A1 (en) * 2013-08-30 2015-03-05 Amgen Inc. Gitr antigen binding proteins
WO2015187835A2 (en) * 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
CA2263129C (en) 1996-08-16 2007-01-09 Schering Corporation Mammalian cell surface antigens; related reagents
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
EP1032672B1 (en) 1997-11-18 2008-12-31 Genentech, Inc. Dna19355 polypeptide, a tumor necrosis factor homolog
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
JP4638876B2 (ja) 2003-05-23 2011-02-23 ワイス Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用
US20060099171A1 (en) 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER
US20100061984A1 (en) 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
AU2008275589B2 (en) 2007-07-12 2013-11-21 Gitr, Inc. Combination therapies employing GITR binding molecules
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
KR101956751B1 (ko) 2011-10-07 2019-03-11 고쿠리츠다이가쿠호진 미에다이가쿠 키메라 항원 수용체
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CA2949998A1 (en) 2014-05-28 2015-12-03 Agenus Inc. Anti-gitr antibodies and methods of use thereof
WO2016054638A1 (en) 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PT3212233T (pt) 2014-10-31 2020-07-16 Oncomed Pharm Inc Terapia combinada para o tratamento de doenças
AU2017278193B9 (en) 2016-06-10 2024-02-01 Regeneron Pharmaceuticals, Inc. Anti-GITR antibodies and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105021A2 (en) * 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
US8709424B2 (en) * 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
US20150064204A1 (en) * 2013-08-30 2015-03-05 Amgen Inc. Gitr antigen binding proteins
WO2015187835A2 (en) * 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LU, LEI, ET AL., COMBINED PD-1 BLOCKADE AND GITR TRIGGERING INDUCE A POTENT ANTITUMOR IMMUNITY IN MURINE CANCER MODELS AND SYNERGIZES WITH CHEMOTHERAPEUTIC DRUGS., 7 February 2014 (2014-02-07) *

Also Published As

Publication number Publication date
EP4344748A2 (en) 2024-04-03
CL2018003515A1 (es) 2019-03-08
US20210147565A1 (en) 2021-05-20
AU2017278193A1 (en) 2018-12-13
CN109563170B (zh) 2023-10-13
CN109563170A (zh) 2019-04-02
WO2017214548A1 (en) 2017-12-14
MA45233A (fr) 2019-04-17
CO2018013298A2 (es) 2019-02-19
CA3027121A1 (en) 2017-12-14
EP4344748A3 (en) 2024-06-12
EP3468999A1 (en) 2019-04-17
JP2019521098A (ja) 2019-07-25
JP2022159476A (ja) 2022-10-17
SG11201810525XA (en) 2018-12-28
IL263273B1 (en) 2025-06-01
MX2018015350A (es) 2019-08-26
IL263273A (en) 2018-12-31
KR20190020297A (ko) 2019-02-28
UA128687C2 (uk) 2024-10-02
JP7162535B2 (ja) 2022-10-28
AU2017278193B2 (en) 2024-01-18
PH12018502502A1 (en) 2019-04-08
US10738126B2 (en) 2020-08-11
US20230042324A1 (en) 2023-02-09
BR112018075434A2 (pt) 2019-03-19
EP3468999B1 (en) 2024-01-10
KR102495601B1 (ko) 2023-02-06
MX2022014695A (es) 2022-12-16
MY200162A (en) 2023-12-09
ZA201807920B (en) 2024-01-31
US20170355774A1 (en) 2017-12-14
NZ748619A (en) 2024-05-31
US11414494B2 (en) 2022-08-16
AU2017278193B9 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
US20230042324A1 (en) Anti-gitr antibodies and uses thereof
US12441800B2 (en) Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof
US20230279113A1 (en) Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof
EP3778641A1 (en) Bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
JP2024097985A (ja) 抗ｇｉｔｒ抗体およびその使用
HK40005871A (en) Anti-gitr antibodies and uses thereof
HK40005871B (en) Anti-gitr antibodies and uses thereof
EA039583B1 (ru) Антитела против gitr и их применения
NZ788539A (en) Anti-gitr antibodies and uses thereof
EA047743B1 (ru) Антитела к gitr и варианты их применения
HK40045394A (en) Bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof